These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32686724)

  • 1. Inhibition of mitotic kinase Mps1 promotes cell death in neuroblastoma.
    Simon Serrano S; Sime W; Abassi Y; Daams R; Massoumi R; Jemaà M
    Sci Rep; 2020 Jul; 10(1):11997. PubMed ID: 32686724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of novel MPS1 inhibitors with preclinical anticancer activity.
    Jemaà M; Galluzzi L; Kepp O; Senovilla L; Brands M; Boemer U; Koppitz M; Lienau P; Prechtl S; Schulze V; Siemeister G; Wengner AM; Mumberg D; Ziegelbauer K; Abrieu A; Castedo M; Vitale I; Kroemer G
    Cell Death Differ; 2013 Nov; 20(11):1532-45. PubMed ID: 23933817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.
    Jemaà M; Manic G; Lledo G; Lissa D; Reynes C; Morin N; Chibon F; Sistigu A; Castedo M; Vitale I; Kroemer G; Abrieu A
    Oncotarget; 2016 Jan; 7(1):885-901. PubMed ID: 26637805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mps1 kinase regulates tumor cell viability via its novel role in mitochondria.
    Zhang X; Ling Y; Guo Y; Bai Y; Shi X; Gong F; Tan P; Zhang Y; Wei C; He X; Ramirez A; Liu X; Cao C; Zhong H; Xu Q; Ma RZ
    Cell Death Dis; 2016 Jul; 7(7):e2292. PubMed ID: 27383047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.
    Maachani UB; Kramp T; Hanson R; Zhao S; Celiku O; Shankavaram U; Colombo R; Caplen NJ; Camphausen K; Tandle A
    Mol Cancer Res; 2015 May; 13(5):852-62. PubMed ID: 25722303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
    Martinez R; Blasina A; Hallin JF; Hu W; Rymer I; Fan J; Hoffman RL; Murphy S; Marx M; Yanochko G; Trajkovic D; Dinh D; Timofeevski S; Zhu Z; Sun P; Lappin PB; Murray BW
    PLoS One; 2015; 10(9):e0138616. PubMed ID: 26398286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
    Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
    Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
    Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.
    Wengner AM; Siemeister G; Koppitz M; Schulze V; Kosemund D; Klar U; Stoeckigt D; Neuhaus R; Lienau P; Bader B; Prechtl S; Raschke M; Frisk AL; von Ahsen O; Michels M; Kreft B; von Nussbaum F; Brands M; Mumberg D; Ziegelbauer K
    Mol Cancer Ther; 2016 Apr; 15(4):583-92. PubMed ID: 26832791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monopolar spindle 1 (MPS1) kinase promotes production of closed MAD2 (C-MAD2) conformer and assembly of the mitotic checkpoint complex.
    Tipton AR; Ji W; Sturt-Gillespie B; Bekier ME; Wang K; Taylor WR; Liu ST
    J Biol Chem; 2013 Dec; 288(49):35149-58. PubMed ID: 24151075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.
    Slee RB; Grimes BR; Bansal R; Gore J; Blackburn C; Brown L; Gasaway R; Jeong J; Victorino J; March KL; Colombo R; Herbert BS; Korc M
    Mol Cancer Ther; 2014 Feb; 13(2):307-315. PubMed ID: 24282275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.
    Tannous BA; Kerami M; Van der Stoop PM; Kwiatkowski N; Wang J; Zhou W; Kessler AF; Lewandrowski G; Hiddingh L; Sol N; Lagerweij T; Wedekind L; Niers JM; Barazas M; Nilsson RJ; Geerts D; De Witt Hamer PC; Hagemann C; Vandertop WP; Van Tellingen O; Noske DP; Gray NS; Würdinger T
    J Natl Cancer Inst; 2013 Sep; 105(17):1322-31. PubMed ID: 23940287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.
    Maia ARR; Linder S; Song JY; Vaarting C; Boon U; Pritchard CEJ; Velds A; Huijbers IJ; van Tellingen O; Jonkers J; Medema RH
    Br J Cancer; 2018 Jun; 118(12):1586-1595. PubMed ID: 29736010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Energy‑stress‑mediated activation of AMPK sensitizes MPS1 kinase inhibition in triple‑negative breast cancer.
    Lim JS; Kim E; Song JS; Ahn S
    Oncol Rep; 2024 Aug; 52(2):. PubMed ID: 38904203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.
    Faisal A; Mak GWY; Gurden MD; Xavier CPR; Anderhub SJ; Innocenti P; Westwood IM; Naud S; Hayes A; Box G; Valenti MR; De Haven Brandon AK; O'Fee L; Schmitt J; Woodward HL; Burke R; vanMontfort RLM; Blagg J; Raynaud FI; Eccles SA; Hoelder S; Linardopoulos S
    Br J Cancer; 2017 Apr; 116(9):1166-1176. PubMed ID: 28334731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Kojima E; Mitsuoka Y; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Yoshizawa H; Murai H; Nakamura Y
    Bioorg Med Chem; 2015 May; 23(9):2247-60. PubMed ID: 25801152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).
    Naud S; Westwood IM; Faisal A; Sheldrake P; Bavetsias V; Atrash B; Cheung KM; Liu M; Hayes A; Schmitt J; Wood A; Choi V; Boxall K; Mak G; Gurden M; Valenti M; de Haven Brandon A; Henley A; Baker R; McAndrew C; Matijssen B; Burke R; Hoelder S; Eccles SA; Raynaud FI; Linardopoulos S; van Montfort RL; Blagg J
    J Med Chem; 2013 Dec; 56(24):10045-65. PubMed ID: 24256217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferential killing of p53-deficient cancer cells by reversine.
    Jemaà M; Galluzzi L; Kepp O; Boilève A; Lissa D; Senovilla L; Harper F; Pierron G; Berardinelli F; Antoccia A; Castedo M; Vitale I; Kroemer G
    Cell Cycle; 2012 Jun; 11(11):2149-58. PubMed ID: 22592527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MPS1 kinase as a potential therapeutic target in medulloblastoma.
    Alimova I; Ng J; Harris P; Birks D; Donson A; Taylor MD; Foreman NK; Venkataraman S; Vibhakar R
    Oncol Rep; 2016 Nov; 36(5):2633-2640. PubMed ID: 27633003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
    Győrffy B; Bottai G; Lehmann-Che J; Kéri G; Orfi L; Iwamoto T; Desmedt C; Bianchini G; Turner NC; de Thè H; André F; Sotiriou C; Hortobagyi GN; Di Leo A; Pusztai L; Santarpia L
    Mol Oncol; 2014 May; 8(3):508-19. PubMed ID: 24462521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.